Advertisement

Topics

Nektar Therapeutics Company Profile

15:31 EST 16th February 2019 | BioPortfolio

We are a biopharmaceutical company with a different approach to medicine. We develop drugs that are easier to take, safer to use, longer lasting and more effective. We look closely at existing therapies, and leverage our knowledge and extensive development expertise to evaluate how they can more effectively impact patients’ lives. Just over 15 years ago, our company was founded on breakthrough ideas that changed the way people thought about disease treatment and introduced new and exciting ways to increase the therapeutic value of medicines. Today, we are developing our own high-value, proprietary products as well as highly differentiated products in partnership with leading pharmaceutical and biotechnology companies. Our product ideas come from a multi-disciplinary team of inventive thinkers and problem solvers. We are fortunate to have world-leading scientists on our research and development staff and a company culture that nurtures innovation. Our development programs focus on products that fill unmet needs in diabetes, infectious disease, oncology, and eventually other areas, where they can have significant impact. We collaborate with partners who recognize the value we bring to product development. By sharing our assets and intellectual resources, we increase the therapeutic value of proven drugs and create new products that redefine what medicines are capable of doing. As our product portfolio and pipeline continue to grow, so does our capacity for innovation. We continue to expand our worldwide capabilities, explore new opportunities, and bring fresh perspectives to medicine.

Location

150 Industrial Road
San Carlos
CA
94070
United States of America

Contact

Phone: 650.631.3100
Fax: 650.631.3150
Email: NektarSC@nektar.com


News Articles [716 Associated News Articles listed on BioPortfolio]

Nektar, Pfizer team up in trial collaboration

Nektar Therapeutics and Pfizer Inc. are teaming up to evaluate several combination therapies containing Nektar’s NKTR214 for various cancers, including metastatic castration-resistant prostate cance...

BioXcel Expands Collaboration With Nektar To Initiate New Clinical Program

WASHINGTON (dpa-AFX) - BioXcel Therapeutics, Inc. (BTAI) and Nektar Therapeutics (NKTR) announced they are expanding the ongoing research collaboration into a new clinical partnership. The collabo...

NKTR-214 Will Not Be Effective, Says New Report on Nektar Therapeutics

A recent report reveals that Nektar Therapeutics, a biopharmaceutical company that uses research to progress cutting-edge medicines in areas of high need, has a primary drug that just doesn’t functi...

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline ...

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline Read more...

Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration

NEW YORK CITY (dpa-AFX) - Nektar Therapeutics (NKTR) said that it has entered into an oncology clinical collaboration with Pfizer Inc. (PFE) to evaluate several combination regimens in multiple ca...

Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA

SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Dru...

Pfizer, Nektar to partner on prostate cancer triple combo drug study

Pfizer and Nektar Therapeutics entered a clinical collaboration to develop a potential triple drug combination for patients w -More- 

Nektar Taps New Head of Oncology Following Data Boost for NKTR-214 at SITC

It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [454 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Response to Chua et al. re: "The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study".

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1299 Associated Companies listed on BioPortfolio]

Pearl Therapeutics, Inc.

Pearl Therapeutics is developing a pipeline of advanced respiratory products that will offer patients and their healthcare providers a choice of formulations and dosage strengths better suited to ...

NEKTAR

We are a biopharmaceutical company with a different approach to medicine. We develop drugs that are easier to take, safer to use, longer lasting and more effective. We look closely at existing therapi...

Nektar Therapeutics

We are a biopharmaceutical company with a different approach to medicine. We develop drugs that are easier to take, safer to use, longer lasting and more effective. We look closely at existing therapi...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Nektar Therapeutics" on BioPortfolio

We have published hundreds of Nektar Therapeutics news stories on BioPortfolio along with dozens of Nektar Therapeutics Clinical Trials and PubMed Articles about Nektar Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nektar Therapeutics Companies in our database. You can also find out about relevant Nektar Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record